ITB-Iplus/GDF-MED/2025/1_Annex E. Declaration of supply restrictions to countries

ITB-Iplus/GDF-MED/2025/1_Annex D. i+solutions model Long-Term Agreement

ITB-Iplus/GDF-MED/2025/1 _Annex C. List of priority countries for TB medicines registration updated

ITB-Iplus/GDF-MED/2025/1 _Annex B - List and technical specifications of products requested

ITB-Iplus/GDF-MED/2025/1_Annex A. Financial Bid Response Form

ITB-Iplus/GDF-MED/2025/1_ITB document pretomanid 200mg

Closing the gaps in childhood TB detection

Creswell, J.; Colvin, C.

TPMAT Recommendations - Round 30 (EOI Released February 2025)

Integrating socio-economic support into drug-resistant TB care to optimise treatment outcomes

Limo, J.; Pahe, C.; Kathure, I.; Ndungu, L.; Mahihu, A.; Mwashumbe, C.; Mueni, E. and Momanyi, H.

2025-01_QA Notice_USFDA Warning letter_Mylan Indore Pithampur site